Trials / Completed
CompletedNCT00902005
Endothelial Function, Inflammatory Disease Activity, and Bone and Cartilage Markers in Rheumatic Patients: The Influence of Antirheumatic Treatment
Endothelial Function, Inflammatory Disease Activity, and Bone and Cartilage Markers in RA and Spondyloarthritis Patients, Treated With TNFalpha-inhibitors in Combination With Methotrexate or Methotrexate or TNFalpha-inhibitors Alone - a Prospective Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 145 (actual)
- Sponsor
- Revmatismesykehuset AS · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to examine the associations between inflammatory disease activity and endothelial function in rheumatoid arthritis (RA) and spondyloarthritis patients treated with methotrexate and Tumor Necrosis Factor alpha (TNFalpha)inhibitor in combination or methotrexate or TNFalpha-inhibitor alone. Further, to look for improvement in endothelial function, and decrease in bone and cartilage destruction during treatment with the combination therapy of TNFalpha-inhibitor and methotrexate in RA and Psoriatic Arthritis (PSA) patients. Last, examine the TNFalpha inhibitors influence on endothelial function and levels of bone and cartilage markers in patients with Ankylosing Spondylitis (AS).
Conditions
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Ankylosing Spondylitis
- Endothelial Dysfunction
- Inflammatory Disease Activity
Timeline
- Start date
- 2008-04-01
- Primary completion
- 2011-06-01
- Completion
- 2012-08-01
- First posted
- 2009-05-14
- Last updated
- 2013-11-21
Locations
1 site across 1 country: Norway
Source: ClinicalTrials.gov record NCT00902005. Inclusion in this directory is not an endorsement.